Cas:1217835-98-7 Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate manufacturer & supplier

Chemical Name:Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate

CAS.NO:1217835-98-7

Synonyms:Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate

Molecular Formula:C₁₃H₁₆N₂O₃

Molecular Weight:248.27800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:73.62000

Exact Mass:248.11600

LogP:2.21800

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate Use and application,Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate technical grade,usp/ep/jp grade.

Related News: The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate manufacturer It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate supplier Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology. Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate vendor Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology. Benzyl (3R)-3-carbamoyl-1-pyrrolidinecarboxylate factory Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology.